Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 269-276

  Pink, J ^a   Pirmohamed, M ^b   Hughes, D A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

AGE FACTORS; AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPUTER SIMULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MORPHOLINES; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TIME FACTORS; WARFARIN;

EID: 84880761205     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.83     Document Type: Article

References (41)

1. Lip, g.Y.H. & Tse, H.F. Management of atrial fibrillation. Lancet 370 (9587), 604-618 (2007).
2. Naccarelli, g.V., Varker, H., Lin, J. & Schulman, K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104, 1534-1539 (2009).
3. Coyne, K.S., Paramore, C., grandy, S., Mercader, M., Reynolds, M. & Zimetbaum, P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9, 348-356 (2006). (Pubitemid 44337788)
4. Fuster, V. et al.; American College of Cardiology/American Heart Association Task Force on Practice guidelines; European Society of Cardiology Committee for Practice guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines and the European Society of Cardiology Committee for Practice guidelines (Writing Committee to Revise the 2001 guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257-e354 (2006). (Pubitemid 44252297)
5. gage, B.F., Fihn, S.D. & White, R.H. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann. Intern. Med. 134, 465-474 (2001). (Pubitemid 32225948)
6. Connolly, S.J. et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118, 2029-2037 (2008).
7. Connolly, S.J. et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
8. Patel, M.R. et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
9. granger, C.B. et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
10. Bucher, H.C., guyatt, g.H., griffith, L.E. & Walter, S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683-691 (1997). (Pubitemid 27341818)
11. Mantha, S. & Ansell, J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb. Haemost. 108, 476-484 (2012).
12. Lip, g.Y., Larsen, T.B., Skjøth, F. & Rasmussen, L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 60, 738-746 (2012).
13. Banerjee, A., Lane, D.A., Torp-Pedersen, C. & Lip, g.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107, 584-589 (2012).
14. Jansen, J.P. et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons good Research Practices: part 1. Value Health 14, 417-428 (2011).
15. Altman, D.g. & Bland, J.M. Absence of evidence is not evidence of absence. BMJ 311, 485 (1995).
16. Miller, C.S., grandi, S.M., Shimony, A., Filion, K.B. & Eisenberg, M.J. Metaanalysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110, 453-460 (2012).
17. O'Dell, K.M., Igawa, D. & Hsin, J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin. Ther. 34, 894-901 (2012).
18. Song, F., Altman, D.g., glenny, A.M. & Deeks, J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326, 472 (2003).
19. guzauskas, g.F., Hughes, D.A., Bradley, S.M. & Veenstra, D.L. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clin. Pharmacol. Ther. 91, 829-837 (2012).
20. Caro, J.J., Möller, J. & getsios, D. Discrete event simulation: the preferred technique for health economic evaluations. Value Health 13 (8), 1056-1060 (2010).
21. Pink, J., Lane, S., Pirmohamed, M. & Hughes, D.A. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343, d6333 (2011).
22. Baczek, V.L., Chen, W.T., Kluger, J. & Coleman, C.I. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam. Pract. 13, 5 (2012).
23. Osterberg, L.g., Urquhart, J. & Blaschke, T.F. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 88, 457-459 (2010).
24. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579 (2011).
25. Radecki, R.P. Dabigatran: uncharted waters and potential harms. Ann. Intern. Med. 157, 66-68 (2012).
26. Uchino, K. & Hernandez, A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172, 397-402 (2012).
27. Cairns, J. ACP Journal Club. Review: Dabigatran increases MI and reduces mortality compared with warfarin, enoxaparin, or placebo. Ann. Intern. Med. 156, JC6-J11 (2012).
28. International Warfarin Pharmacogenetics Consortium et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360 (8), 753-764 (2009).
29. Hughes, D.A., Bayoumi, A.M. & Pirmohamed, M. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123-127 (2007). (Pubitemid 47075340)
30. Singer, D.E. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med. 151, 297-305 (2009).
31. U.S. Department of Health and Human Services. National Diabetes Statistics http://diabetes.niddk.nih.gov/dm/pubs/statistics (2011). Accessed 5 July 2012.
32. Hajjar, I., Kotchen, J.M. & Kotchen, T.A. Hypertension: trends in prevalence, incidence and control. Annu. Rev. Public Health 27, 465-490 (2006).
33. Wilmoth, J.R. & Shkolnikov, V. The human mortality database http://www.mortality.org (2006). Accessed 5 July 2012.
34. Hart, R.g., Pearce, L.A. & Aguilar, M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007). (Pubitemid 351650486)
35. Connolly, S.J. et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
36. Lipscomb, J., Weinstein, M.C. & Torrance, g.W. Time preference (Chapter 7). In Cost-Effectiveness in Health and Medicine (eds. gold, M.R., Siegel, J.E., Russell, L.B. & Weinstein, M.C.) (Oxford University Press, New York, 1996).
37. Sullivan, P.W. & ghushchyan, V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making 26, 410-420 (2006). (Pubitemid 44050845)
38. Meckley, L.M., gudgeon, J.M., Anderson, J.L., Williams, M.S. & Veenstra, D.L. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28, 61-74 (2010).
39. gage, B.F., Cardinalli, A.B. & Owens, D.K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch. Intern. Med. 156, 1829-1836 (1996). (Pubitemid 26295228)
40. Freeman, J.V. et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med. 154, 1-11 (2011).
41. Shah, S.V. & gage, B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123, 2562-2570 (2011). 276 VOLUME 94 NUMBER 2 | AUgUST 2013 | www.nature.com/cpt